tiprankstipranks
Trending News
More News >

Karyopharm price target adjusted to $10 from $5 at Barclays

Barclays raised the firm’s price target on Karyopharm (KPTI) to $10 from $5 and keeps an Overweight rating on the shares. The company’s Q1 selinexor revenue of $21.1M was below consensus of $28.7M, but the key focus for investors is on pivotal myelofibrosis data in late 2025/early 2026, the analyst tells investors in a research note. The firm adjusted its model to account for the recent stock split.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue